CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Everolimus

Last Updated: March 19, 2014
Result type: Reports
Project Number: SR0376-000
Product Line: Common Drug Review

Generic Name: Everolimus

Brand Name: Afinitor

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: April 15, 2015

Recommendation Type: Do not list